Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PT Lippo Karawaci TbkPTLKF 71 Debt-to-EBITDA is 3.77 as of Jun. 2026, which is 23% below its 10-year median of 4.88. GuruFocus rates PTLKF with a GF Score™ of 71/100 and a GF Value™ of $0.01. The stock has 3 warning signs investors should review. Among 478 Healthcare Providers & Services companies, PT Lippo Karawaci Tbk ranks worse than 73.43% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for PT Lippo Karawaci Tbk's Debt-to-EBITDA or its related term are showing as below:
PTLKF'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -78.16 Med: 4.88 Max: 19.24
Current: 4.56
During the past 13 years, the highest Debt-to-EBITDA Ratio of PT Lippo Karawaci Tbk was 19.24. The lowest was -78.16. And the median was 4.88.
PTLKF's Debt-to-EBITDA is ranked worse than 73.43% of 478
companies
in the Healthcare Providers & Services industry
Industry Median: 2.185
vs PTLKF: 4.56
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
PT Lippo Karawaci Tbk Debt-to-EBITDA Related Terms
PT Lippo Karawaci Tbk Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for PT Lippo Karawaci Tbk's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Care Facilities subindustry, PT Lippo Karawaci Tbk's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Lippo Karawaci Tbk Debt-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, PT Lippo Karawaci Tbk's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where PT Lippo Karawaci Tbk's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
PT Lippo Karawaci Tbk (PTLKF) has a Debt-to-EBITDA of 3.77 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on PT Lippo Karawaci Tbk. This is 23% below median its historical median of 4.88. According to the industry distribution chart, PT Lippo Karawaci Tbk ranks #351 out of 478 companies in the Healthcare Providers & Services industry, placing it in the top 73.4%.
Is PT Lippo Karawaci Tbk's Debt-to-EBITDA too high?
PT Lippo Karawaci Tbk's current Debt-to-EBITDA of 3.77 is 23% below median its 10-year median of 4.88. The Healthcare Providers & Services industry median Debt-to-EBITDA is 2.19. PT Lippo Karawaci Tbk's value of 3.77 is 72.5% above this industry median. Based on the distribution chart, PT Lippo Karawaci Tbk ranks #351 out of 478 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, PT Lippo Karawaci Tbk has a GF Score™ of 71/100, reflecting its overall financial health beyond just this single metric.
How does PT Lippo Karawaci Tbk's Debt-to-EBITDA compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, PT Lippo Karawaci Tbk ranks #351 out of 478 companies for Debt-to-EBITDA. This places PT Lippo Karawaci Tbk in the lower half of its industry. The industry median Debt-to-EBITDA is 2.19. PT Lippo Karawaci Tbk's value of 3.77 is 72.5% above this benchmark. While the company's 10-year median is 4.88 vs. the industry median of 2.19, PT Lippo Karawaci Tbk has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Healthcare Providers & Services company?
The median Debt-to-EBITDA among Healthcare Providers & Services companies is 2.19, based on 478 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PT Lippo Karawaci Tbk's current Debt-to-EBITDA of 3.77 is 72.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on PT Lippo Karawaci Tbk. For the Healthcare Providers & Services industry, the median Debt-to-EBITDA is 2.19 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PT Lippo Karawaci Tbk's current Debt-to-EBITDA is 3.77, which is 23% below median its own 10-year median of 4.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Lippo Karawaci Tbk stock overvalued right now?
PT Lippo Karawaci Tbk (PTLKF) has a current Debt-to-EBITDA of 3.77. The stock's GF Value™ is $0.01, compared to a current price of $0.01 — trading 4% above its estimated fair value. The current Debt-to-EBITDA is 3.77, which is 23% below median its 10-year median of 4.88 and 72.5% above the Healthcare Providers & Services industry median of 2.19. PT Lippo Karawaci Tbk's overall GF Score™ is 71/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For PT Lippo Karawaci Tbk (PTLKF), the current Debt-to-EBITDA is 3.77 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Lippo Karawaci Tbk (PTLKF) Overvalued in 2026?
Based on GuruFocus' analysis, PT Lippo Karawaci Tbk stock appears to be overvalued.
The current stock price of $0.01 is trading 4% above its estimated GF Value™ of $0.01.
Key valuation signals for PTLKF:
Debt-to-EBITDA: 3.77 (23% below median its 10-year median of 4.88)
GF Value™: $0.01 vs. price of $0.01 (4% above fair value)
Industry Position: 72.5% above the Healthcare Providers & Services median (#351 of 478)
No single metric tells the full story. See the PTLKF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Lippo Karawaci Tbk is engaged in property development activities including area development, residential property development and sales, commercial property, light industrial property, and integrated property projects. As part of its large scale integrated development portfolio, the Company develops projects within strategic locations comprising residential, office, mall, hotel, entertainment, education, and healthcare facilities. Its portfolio includes residential and urban development, hospitals, malls, and hotels and leisure assets. The Company has developed and manages urban property areas mainly in Java and Sulawesi, and operates across real estate, lifestyle, and healthcare segments, providing services across Indonesia.
71GF Score
Get the complete analysis for PTLKF
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PTLKF has been successfully added to your 
